|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
183,678,000 |
Market
Cap: |
4.53(B) |
Last
Volume: |
775,760 |
Avg
Vol: |
773,595 |
52
Week Range: |
$23.37 - $33.63 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 581 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
35,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
15,666 |
15,666 |
89,488 |
206,962 |
Total Sell Value |
$454,291 |
$454,291 |
$2,700,159 |
$6,056,962 |
Total People Sold |
3 |
3 |
4 |
6 |
Total Sell Transactions |
3 |
3 |
7 |
12 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-18 |
4 |
D |
$32.18 |
$60,144 |
D/D |
(1,869) |
66,292 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,355 |
68,161 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-18 |
4 |
D |
$32.18 |
$60,144 |
D/D |
(1,869) |
106,199 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,355 |
108,068 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-18 |
4 |
D |
$32.18 |
$22,719 |
D/D |
(706) |
5,228 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,034 |
5,934 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-18 |
4 |
D |
$32.18 |
$127,143 |
D/D |
(3,951) |
92,883 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,897 |
96,834 |
|
- |
|
Laurencin Cato T |
Director |
|
2024-02-15 |
4 |
AS |
$31.85 |
$85,677 |
D/D |
(2,690) |
15,169 |
|
-24% |
|
Laurencin Cato T |
Director |
|
2024-02-15 |
4 |
OE |
$22.52 |
$60,579 |
D/D |
2,690 |
17,859 |
|
- |
|
Mckeon Brian P |
Director |
|
2024-02-10 |
4 |
D |
$27.32 |
$29,724 |
D/D |
(1,088) |
23,141 |
|
- |
|
Mckeon Brian P |
Director |
|
2024-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,533 |
24,229 |
|
- |
|
Daglio David Angelo Jr. |
Director |
|
2024-02-10 |
4 |
D |
$27.32 |
$29,724 |
D/D |
(1,088) |
23,141 |
|
- |
|
Daglio David Angelo Jr. |
Director |
|
2024-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,533 |
24,229 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-08 |
4 |
D |
$26.77 |
$294,657 |
D/D |
(11,007) |
139,945 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
36,835 |
150,952 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-08 |
4 |
D |
$26.77 |
$85,209 |
D/D |
(3,183) |
268,744 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
21,485 |
271,927 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-08 |
4 |
D |
$26.77 |
$409,046 |
D/D |
(15,280) |
87,937 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
46,658 |
103,217 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-08 |
4 |
D |
$26.77 |
$217,827 |
D/D |
(8,137) |
101,713 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
27,012 |
109,850 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-08 |
4 |
D |
$26.77 |
$227,090 |
D/D |
(8,483) |
147,707 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
28,240 |
156,190 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2024-02-08 |
4 |
D |
$26.77 |
$2,456,335 |
D/D |
(91,757) |
1,179,675 |
|
- |
|
2018 Records found
|
|
Page 3 of 81 |
|
|